Crossmark

IgG4-related disease: Is rituximab the best therapeutic strategy for cases refractory to conventional therapy? Results of a systematic review

Crossref DOI link: https://doi.org/10.1016/j.reumae.2018.11.019

Published Print: 2020-05

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Betancur-Vásquez, Laura

Gonzalez-Hurtado, Daniel

Arango-Isaza, Daniela

Rojas-Villarraga, Adriana

Hernandez-Parra, Deicy

Carmona, Samuel

Díaz-Coronado, J.C.
License Information

Text and Data Mining valid from 2020-05-01
More Information

This article is maintained by: Elsevier

Article Title: IgG4-related disease: Is rituximab the best therapeutic strategy for cases refractory to conventional therapy? Results of a systematic review

Journal Title: Reumatología Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.reumae.2018.11.019

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.reuma.2018.11.011

Content Type: article

Copyright: © 2018 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.